US Patent 4,395,420: Doxepin Topical Pruritus Patent Scope, Expiration, and Patent Landscape

US Patent 4,395,420 covers topical doxepin, particularly doxepin hydrochloride, for treating pruritus and related itching conditions. Its claims cover both the therapeutic method and the topical composition, with concentration ranges from approximately 0.1% to 10% by weight and dosage forms including creams, ointments, and aqueous-alcohol solutions. The patent issued on July 26, 1983, and its ordinary 17-year term expired on July 26, 2000. It no longer creates a blocking patent right in the United States.[1][2]

The patent remains relevant as prior art for topical doxepin formulations, infringement analysis involving historical products, and assessment of the technical origin of products such as 5% doxepin hydrochloride cream. It does not provide current exclusivity against generic topical doxepin products.

What does US Patent 4,395,420 protect?

The patent protects two related subject matter groups:

A method of treating human pruritus by applying doxepin or a physiologically acceptable acid addition salt topically.
A topical composition containing doxepin or such a salt in a pharmaceutically acceptable skin carrier.

The independent claims are claim 1 and claim 9.

Claim group	Independent claim	Protected subject matter
Method	1	Topical application of doxepin or an acceptable acid addition salt to treat pruritus in humans
Composition	9	Topical carrier containing a therapeutic amount of doxepin or an acceptable acid addition salt
Concentration limitations	2-4, 10-12	At least about 0.1%; approximately 0.1%-10%; or approximately 0.5%-5%
Salt limitations	5-6, 13-14	Specified salts, including doxepin hydrochloride
Dosage-form limitations	7-8, 15-16	Ointment, cream, or aqueous-alcohol solution

The claims are directed to topical use of the known tricyclic compound doxepin for an indication distinct from its systemic antidepressant use.

What are the independent claims in US 4,395,420?

Claim 1: method of treating pruritus

Claim 1 requires four core elements:

A human patient in need of treatment.
Pruritus as the condition being treated.
Topical application.
A therapeutically effective amount of doxepin or a physiologically acceptable acid addition salt.

The claim does not limit the cause of the pruritus. It is not restricted to eczema, atopic dermatitis, allergic dermatitis, psoriasis, insect bites, or a specific dermatological diagnosis. On its face, the claim reaches topical treatment of human itching across multiple underlying conditions, provided the use is therapeutic and the active ingredient is doxepin or an eligible salt.

The claim also does not specify:

A particular concentration.
A particular dosage form.
A particular application frequency.
A particular treated body surface.
A specific duration of treatment.
A requirement that the doxepin be doxepin hydrochloride.

The dependent claims add those limitations.

Claim 9: topical composition

Claim 9 requires:

A carrier pharmaceutically acceptable for topical application to skin.
Doxepin or a physiologically acceptable acid addition salt.
A therapeutic amount of the active ingredient.

Unlike claim 1, claim 9 does not expressly require that the composition be used to treat a particular patient. It is a composition claim directed to the product itself. The phrase "for treating pruritis" may operate as a functional or intended-use limitation, depending on the infringement and validity context.

The composition claim is broader in dosage-form terms than claims 15 and 16. It is not limited to a cream, ointment, or aqueous-alcohol solution unless those limitations are imported through a dependent claim.

How do the concentration claims operate?

Claims 2 through 4 and 10 through 12 create overlapping concentration ranges.

Claims	Concentration
2 and 10	Not less than about 0.1% by weight
3 and 11	About 0.1% to about 10% by weight
4 and 12	About 0.5% to about 5% by weight

The hierarchy is significant:

A product containing 0.05% doxepin would fall outside the express concentration limitations of claims 2-4 and 10-12, although it could still implicate claims 1 or 9 if the amount were therapeutically effective.
A 0.1% product would generally fall within the stated lower boundary, subject to the interpretation of "about."
A 0.5% to 5% product falls within all three concentration concepts, assuming the formulation otherwise meets the claim requirements.
A 5% product falls within the 0.1%-10% range and the 0.5%-5% range.
A product above 5% but no more than approximately 10% would fall within claims 3 and 11, but not claims 4 and 12.

The patent uses "about," which creates an evidentiary boundary around the numerical limits. The practical scope depends on formulation testing, analytical precision, and the ordinary meaning of the range in the field.

What salts and formulations are protected?

Doxepin hydrochloride

Claims 6 and 14 specifically cover doxepin hydrochloride at approximately 0.5% to 10% by weight. This is the most commercially important salt limitation because topical doxepin products have historically used doxepin hydrochloride.

A 5% doxepin hydrochloride cream is within the express concentration range of these claims. The product would also fall within the broader composition and method claims if the remaining claim elements were present.

Other acid addition salts

Claims 5 and 13 cover:

Halides other than fluoride.
Acetate.
Valerate.
Oleate.

The exclusion of fluoride means that a doxepin fluoride salt is outside the expressly enumerated salt group in these dependent claims. It could still require analysis under claims 1 or 9 if it qualified as a physiologically acceptable acid addition salt.

Dosage forms

Claims 7 and 15 cover an ointment or cream. Claims 8 and 16 cover an aqueous-alcohol solution.

The independent composition claim is not expressly confined to those vehicles. Potentially relevant topical carriers could include gels, lotions, emulsions, foams, sprays, hydrogels, or other dermatological vehicles, subject to the construction of "carrier pharmaceutically acceptable for topical application to the skin."

The patent therefore has broader conceptual coverage than a commercial cream claim. The dependent dosage-form claims provide narrower fallback positions.

How strong is the claim scope?

The patent had commercially useful breadth when enforceable, but its current patent strength is zero because the patent expired in 2000.

Scope strengths during the patent term

The claims had several characteristics favorable to the patent owner:

The method claim covered the therapeutic use rather than only a particular product.
The pruritus indication was broad.
The active ingredient could be doxepin or an acceptable acid addition salt.
The composition claim was not limited to one named brand or one manufacturing process.
The concentration claims covered commercially practical strengths, including 5%.
The dosage-form claims addressed conventional topical products.

Potential claim vulnerabilities

The claims also had potential weaknesses:

Doxepin was known before the patent, so novelty and obviousness would turn on the topical antipruritic use and formulation disclosure.
"Therapeutically effective amount" is functional language that can create proof issues.
"About" makes concentration boundaries less exact.
"Pharmaceutically acceptable carrier" is broad and may create enablement or written-description questions if asserted against an unconventional vehicle.
A composition claim directed partly by intended use may face claim-construction disputes over whether the stated treatment purpose imposes structural limitations.
Prior topical use of related antihistamines or tricyclic compounds could have been relevant to obviousness.

These issues mattered during the enforceable term. They do not revive the patent today.

When did US Patent 4,395,420 expire?

US Patent 4,395,420 issued on July 26, 1983. As a pre-1995 United States patent, its ordinary term was 17 years from issuance under the then-applicable patent-term rule. The resulting expiration date was July 26, 2000, absent a terminal disclaimer or a special term adjustment.[1][2]

Event	Date
Patent issued	July 26, 1983
Ordinary patent term	17 years from issuance
Expiration	July 26, 2000
Current status	Expired
Current blocking right	None

The expiration eliminates infringement risk based solely on US 4,395,420. It also means that a manufacturer does not need a license from the patent owner to practice the claimed topical doxepin technology in the United States.

What is the FDA and Orange Book status of topical doxepin?

Topical doxepin hydrochloride cream was approved by FDA as a prescription product for short-term management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. Zonalon Cream, containing doxepin hydrochloride at 5%, is the principal branded reference associated with this topical product category.[3][4]

FDA regulatory status and patent status are separate:

FDA approval does not extend an expired patent.
An Orange Book listing does not prevent use of an expired patent disclosure.
Any remaining regulatory exclusivity would have to arise from FDA exclusivity, not from US 4,395,420.
The existence, removal, or current status of a particular Orange Book entry must be assessed from the current FDA publication rather than inferred from the patent.

Topical doxepin is a small-molecule drug, not a biologic. Biosimilar pathways under the Public Health Service Act are therefore not applicable. A competing product would generally proceed through the abbreviated new drug application pathway if an eligible reference product and dosage-form framework were available, or through a different FDA application pathway where an ANDA route was not appropriate.[3][5]

Are there Paragraph IV risks for generic doxepin cream?

US 4,395,420 cannot support a current Paragraph IV challenge because it expired more than two decades ago. A Paragraph IV certification is relevant to an unexpired patent listed for an approved drug product. An expired patent does not create a live patent obstacle to generic entry.

Historical Paragraph IV activity, if any, would have concerned later-expiring patents, regulatory exclusivity, or other listed patents rather than the expired 1983 patent itself. The claims of US 4,395,420 would not support a modern 30-month stay under the Hatch-Waxman framework.

A generic topical doxepin applicant would instead focus on:

Reference-product selection.
Bioequivalence or pharmaceutical equivalence requirements.
Active ingredient identity and strength.
Vehicle composition.
Microbiological quality.
Inactive-ingredient differences.
Labeling and indication alignment.
Any currently unexpired patents listed for the reference product.

What generic launch scenarios exist?

Because US 4,395,420 is expired, the principal launch scenarios are regulatory and commercial rather than patent-driven.

Launch scenario	Patent effect of US 4,395,420	Main issue
5% doxepin hydrochloride cream	No blocking effect	FDA approval and market demand
Lower-strength topical doxepin	No blocking effect	Formulation, labeling, and clinical support
Non-cream topical vehicle	No blocking effect	Product-specific FDA pathway
Compounded topical doxepin	No patent barrier from this patent	Compounding-law and quality requirements
Authorized generic or licensed product	No license required for this patent	Commercial agreement and FDA status
New indication using topical doxepin	No patent barrier from this patent	Regulatory evidence and any later patents

A manufacturer could practice the disclosed concentration ranges, salt choices, and dosage forms without infringing this expired patent.

Does US 4,395,420 create manufacturing or formulation barriers?

It no longer creates a patent barrier to manufacturing. Its technical disclosure may still identify formulation considerations relevant to product development:

Doxepin hydrochloride is the commercially established salt.
Cream and ointment vehicles are expressly covered in the claims.
Aqueous-alcohol systems are separately claimed.
Concentrations between 0.5% and 5% are central to the claim structure.
A 5% cream is squarely within the historical commercial formulation space.

Current manufacturing barriers are more likely to involve:

Maintaining uniform doxepin distribution.
Controlling viscosity and phase stability.
Managing skin tolerability and sensitization.
Demonstrating preservative effectiveness.
Controlling microbial quality.
Establishing comparative product performance.
Meeting FDA chemistry, manufacturing, and controls requirements.

Those matters are regulatory and technical barriers, not rights created by US 4,395,420.

Which companies challenged or licensed this patent?

The patent claims do not identify licensing arrangements, settlement agreements, Paragraph IV certifications, or litigation outcomes. Patent assignment information, FDA records, ANDA litigation records, and commercial agreements are maintained in separate records.

No current license is required to practice the patent because it expired in 2000. Any historical license, settlement, or litigation involving the patent would have no continuing exclusionary effect unless tied to a separate surviving right, such as a later patent, trademark, contract, or regulatory exclusivity period.

How does this patent compare with later topical doxepin protection?

US 4,395,420 is a foundational use-and-composition patent. Its coverage is broad at the therapeutic-concept level but relatively simple technically.

Protection type	US 4,395,420 coverage
Active ingredient	Doxepin and specified acid addition salts
Indication	Human pruritus
Route	Topical
Concentration	Approximately 0.1%-10%, with narrower ranges
Vehicle	Broad topical carrier; narrower claims for cream, ointment, and aqueous-alcohol solution
Manufacturing process	No process limitation in the supplied claims
Device or delivery system	None
Patient subgroup	None
Current enforceability	Expired

A later patent could have attempted to protect a specific formulation, delivery system, treatment regimen, patient subgroup, combination, or manufacturing process. Such a patent would need separate identification and independent validity and expiration analysis. US 4,395,420 itself does not cover a proprietary device, controlled-release system, combination therapy, or manufacturing process.

What is the commercial exposure associated with the patent?

The patent’s historical commercial exposure was linked primarily to 5% doxepin hydrochloride cream for dermatological pruritus. Its expiration removed any patent-based ability to preserve branded pricing.

Current commercial exposure depends on:

Whether the branded product remains actively marketed.
The number of approved generic or compounded alternatives.
The size of the pruritus treatment market.
Reimbursement and payer substitution.
Physician familiarity with topical doxepin.
Product tolerability and labeling restrictions.
Availability of alternative topical antipruritic therapies.

No current revenue stream can be attributed to patent exclusivity under US 4,395,420.

Key Takeaways

US 4,395,420 covers topical doxepin for treating human pruritus.
Independent claim 1 is a broad method-of-treatment claim.
Independent claim 9 covers a topical doxepin composition.
Dependent claims cover approximately 0.1%-10% concentrations, doxepin hydrochloride, creams, ointments, and aqueous-alcohol solutions.
A 5% doxepin hydrochloride cream falls within the central historical claim scope.
The patent issued on July 26, 1983, and expired on July 26, 2000.
The patent creates no current US infringement, Paragraph IV, licensing, or generic-entry barrier.
Doxepin is a small molecule, so biosimilar risk is not applicable.
Current competitive risk is driven by FDA requirements, formulation performance, market access, and later patents, not by US 4,395,420.

FAQs

Can a company sell 5% doxepin hydrochloride cream in the United States without licensing US 4,395,420?

Yes. The patent expired on July 26, 2000. A company still must satisfy applicable FDA, manufacturing, labeling, and commercial requirements.

Does the patent cover oral doxepin for itching?

No. The claims require topical application or a topical skin carrier. Oral doxepin products are outside the express scope of these claims.

Does the patent cover doxepin free base?

Yes, the independent claims recite doxepin itself as an alternative to an acid addition salt. The patent is expired, so this coverage has no current blocking effect.

Is a doxepin gel potentially covered by the patent?

Historically, a gel could potentially have fallen within the broad carrier language of claims 1 or 9 if the other elements were met. The gel would not necessarily fall within the narrower cream, ointment, or aqueous-alcohol claims. The patent is now expired.

Could a new topical doxepin indication receive patent protection?

A later patent could potentially claim a novel indication, patient subgroup, dosing regimen, formulation, delivery system, or manufacturing method if statutory patentability requirements were satisfied. Such protection would be separate from US 4,395,420.

References

United States Patent No. 4,395,420. (1983). Topical compositions containing doxepin. United States Patent and Trademark Office. https://patents.google.com/patent/US4395420A/en
United States Code, 35 U.S.C. §§ 154, 271. (2024). Patent term and infringement provisions. https://uscode.house.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
DailyMed. (2024). Doxepin hydrochloride cream, 5% prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	1177406	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,395,420

Summary for Patent: 4,395,420